scholarly journals Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy

2020 ◽  
Vol 9 (8) ◽  
pp. 537-551 ◽  
Author(s):  
Lucy Gilbert ◽  
Agnihotram V Ramanakumar ◽  
Maria Carolina Festa ◽  
Kris Jardon ◽  
Xing Zeng ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Healthcare Costs ◽  
Median Overall Survival ◽  
Cytotoxic Chemotherapy ◽  
High Grade ◽  
Chemotherapy Drugs ◽  
Tertiary Center ◽  
Direct Healthcare Costs ◽  
First Relapse ◽  
Mean Cost

Aim: To describe the direct healthcare costs associated with repeated cytotoxic chemotherapy treatments for recurrent high-grade serous cancer (HGSC) of the ovaries. Patients & methods: Retrospective review of 66 women with recurrent stage III/IV HGSC ovarian cancer treated with repeated lines of cytotoxic chemotherapy in a Canadian University Tertiary Center. Results: Mean cost of treatment of first relapse was CAD$52,227 increasing by 38% for two, and 86% for three or more relapses with median overall survival of 36.0, 50.7 and 42.8 months, respectively. In-hospital care accounted for 71% and chemotherapy drugs accounted for 17% of the total costs. Conclusion: After the third relapse of HGSC, cytotoxic chemotherapy did not prolong survival but was associated with substantially increased healthcare costs.

Costs associated with outpatient, emergency room and inpatient care for migraine in the USA

Cephalalgia ◽  
2011 ◽  
Vol 31 (15) ◽  
pp. 1570-1575 ◽  
Author(s):  
Ralph P Insinga ◽  
Daisy S Ng-Mak ◽  
Mary E Hanson
Keyword(s):  
Emergency Room ◽  
Healthcare Costs ◽  
Outpatient Visit ◽  
Inpatient Hospitalization ◽  
Migraine Headaches ◽  
The Us ◽  
Inpatient Hospitalizations ◽  
The Usa ◽  
Direct Healthcare Costs ◽  
Mean Cost

Background: Data on the average US costs of an outpatient visit, emergency room (ER) visit or hospitalization for migraine are scant, with the most recent available values based on healthcare charges reported from 1994 data. Methods: We estimated healthcare costs associated with outpatient and ER visits and inpatient hospitalizations related to migraine retrospectively obtained from the 2007 Medstat MarketScan Commercial Claims & Encounters database. Tabulated costs reflected payments from insurers, patients and other sources. All costs were adjusted to 2010 US dollars. Results: The estimated mean cost (95% CI) for migraine-related care per outpatient visit ( N = 680,946) was $139.88 ($139.35–140.41); per ER visit ( N = 88,128) was $775.09 ($768.10–782.09); and per inpatient hospitalization ( N = 5516) was $7317.07 ($7134.96–7499.17). The most frequently coded procedures at outpatient and ER visits were subcutaneous or intra-muscular injection, and for hospitalizations was computed tomography. Estimated annual US healthcare costs in 2010 for migraine associated with: outpatient visits were $3.2 billion, ER visits were $700 million, and inpatient hospitalizations were $375 million. Conclusions: Direct healthcare costs associated with patient visits and hospitalizations for migraine headaches have increased since previously published estimates. Further research is needed to understand the current overall healthcare cost burden per patient and within the US population.

Loss of BRCA1 promotor hypermethylation in recurrent high grade ovarian cancer

2016 ◽  
Vol 76 (10) ◽  
Author(s):  
S Prieske ◽  
K Prieske ◽  
SA Joosse ◽  
F Trillsch ◽  
D Grimm ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
High Grade

MOLECULAR AND GENETIC SUBTYPES OF OVARIAN CANCER: PROSPECTS FOR FURTHER STUDIES

2019 ◽  
Vol 65 (1) ◽  
pp. 56-62
Author(s):  
Alisa Villert ◽  
Larisa Kolomiets ◽  
Natalya Yunusova ◽  
Yevgeniya Fesik
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Carcinoma ◽  
Molecular Subtypes ◽  
Survival Rates ◽  
Consensus Algorithm ◽  
Histopathological Diagnosis ◽  
Low Grade ◽  
High Grade ◽  
Ovarian Carcinomas ◽  
Genetic Subtypes

High-grade ovarian carcinoma is a histopathological diagnosis, however, at the molecular level, ovarian cancer represents a heterogeneous group of diseases. Studies aimed at identifying molecular genetic subtypes of ovarian cancer are conducted in order to find the answer to the question: can different molecular subgroups influence the choice of treatment? One of the achievements in this trend is the recognition of the dualistic model that categorizes various types of ovarian cancer into two groups designated high-grade (HG) and low-grade (LG) tumors. However, the tumor genome sequencing data suggest the existence of 6 ovarian carcinoma subtypes, including two LG and four HG subtypes. Subtype C1 exhibits a high stromal response and the lowest survival. Subtypes C2 and C4 demonstrate higher number of intratumoral CD3 + cells, lower stromal gene expression and better survival than sybtype C1. Subtype C5 (mesenchymal) is characterized by mesenchymal cells, over-expression of N-cadherin and P-cadherin, low expression of differentiation markers, and lower survival rates than C2 and C4. The use of a consensus algorithm to determine the subtype allows identification of only a minority of ovarian carcinomas (approximately 25%) therefore, the practical importance of this classification requires additional research. There is evidence that it makes sense to randomize tumors into groups with altered expression of angiogenic genes and groups with overexpression of the immune response genes, as in the angiogenic group there is a comparative superiority in terms of survival. The administration of bevacizumab in the angiogenic group improves survival, while the administration of bevacizumab in the immune group even worsens the outcome. Molecular subtypes with worse survival rates (proliferative and mesenchymal) also benefit most from bevacizumab treatment. This review focuses on some of the advances in understanding molecular, cellular, and genetic changes in ovarian carcinomas with the results achieved so far regarding the formulation of molecular subtypes of ovarian cancer, however further studies are needed.

Sign in / Sign up

Export Citation Format

Share Document